US stock results analysis for Industry - Biotech for the month ending Dec 31, 2025
Analysis of which US stocks have performed the best and worst in Industry - Biotech for the month ending Dec 31, 2025 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current month are considered.
1
POSITIVE PROFIT GROWTH
2
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
11.5
%
TOTAL REVENUE GROWTH
63.6
%
TOTAL EBIDT GROWTH
-45.2
%
TOTAL OPER. PROFIT GROWTH
Positive
Negative
Pending
| Stock | Last Result Updated | Market Capitalization | Current Price | Operating Revenue Qtr | Revenue Growth Qtr YoY % | Revenue Surprise Qtr % | Net Profit Qtr | Net Profit Qtr Growth YoY % | Net Profit Surprise Qtr % | Operating Profit Qtr | Operating Profit Growth Qtr YoY % | EBITDA Qtr | EBITDA Qtr growth YoY % | Operating Profit Margin Qtr % | Operating Profit Qtr Margin% YoY Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anixa Biosciences Inc | 12-Jan-2026 |
110.14
|
3.30
|
0.00
|
-
|
-
|
-2.70
|
6.52
|
-
|
-2.88
|
9.07
|
0.00
|
-
|
-
|
-
|
| BriaCell Therapeutics Corp | 11-Dec-2025 |
27.39
|
4.41
|
0.00
|
-
|
-
|
-8.20
|
-41.28
|
-
|
-8.32
|
-61.52
|
0.00
|
-
|
-
|
-
|
| Champions Oncology Inc | 15-Dec-2025 |
96.23
|
6.93
|
15.04
|
11.46
|
7.12
|
0.30
|
-58.93
|
130.00
|
0.19
|
-74.73
|
0.02
|
63.64
|
1.23
|
-4.20
|
